• Home
  • About Journal
    Journal Introduction
    Editorial Board
    Youth Editorial Board
    Cooperating Institutions
    Editorial Department
  • Submission Guidelines
  • Policies & Statements
    Ethical Guidelines for Publication
    Academic Misconduct Statement
    Open Access (OA) Statement
    AIGC Use Statement
  • Journal Subscription
  • Download Center
  • 中文版
Cite this article:
LI Yuexuan,LIANG Lihong,XU Ru,CHENG Peixuan,XIAO Chaoni.Study on pharmacokinetics of α-asaronol from Rhizoma Acori Tatarinowii by intranasal administration in rats[J].Journal Of Pharmaceutical Research,2021,40(10):631-637[Click to copy]
【Print this page】      【Download PDF Full Text】   【View/Add Comment】  【Download reader】  【 Close 】
←Previous|Next→ Archive    Advanced Search
This article has been viewed: 2356times   Download 2648次 QR Code for this article
Scan with your phone!
石菖蒲抗癫痫活性成分α-细辛醇鼻腔给药大鼠的药代动力学研究
李玥璇,梁丽红,许茹,程培萱,肖超妮
Font:Larger+|Default|Smaller-
(西北大学生命科学学院,陕西 西安 710069)
摘要:
目的 研究石菖蒲抗癫痫活性成分α-细辛醇鼻腔给药的药代动力学特征和脑组织分布。方法 采用HPLC方法分析比较鼻腔给药、灌胃给药和静脉注射α-细辛醇大鼠血浆的药代动力学特性和脑组织分布情况。结果 鼻腔给药α-细辛醇Cmax=11.39 ± 1.30 μg·mL-1,Tmax= 2 min,这与静脉给药α-细辛醇的参数相当,而灌胃给药α-细辛醇Cmax= 6.71 ± 0.78 μg·mL-1,Tmax=10 min。鼻腔给药和灌胃给药的生物利用度分别为70.57 %和19.31 %。鼻腔给药α-细辛醇在海马、小脑、嗅球和大脑皮层均有分布,且在嗅球的脑靶向性最高。结论 鼻腔给药α-细辛醇通过鼻脑通路进入脑部,吸收更迅速、生物利用度更高、脑靶向性更好,是一种治疗癫痫疾病的有效途径。
关键词:  α-细辛醇  鼻腔给药  癫痫
DOI:10.13506/j.cnki.jpr.2021.10.001
基金项目:陕西省重点研发计划-国际科技合作计划重点项目(No.2018KWZ-05)
Publication Date:October 25, 2021
Study on pharmacokinetics of α-asaronol from Rhizoma Acori Tatarinowii by intranasal administration in rats
LI Yuexuan,LIANG Lihong,XU Ru,CHENG Peixuan,XIAO Chaoni
(College of Life Sciences, Northwest University, Xi’an, China 710069)
Abstract:
Objective To investigate rat plasma pharmacokinetics and brain distribution of α-asaronol from Rhizoma Acori Tatarinowii by intranasal administration. Methods RP-HPLC method was applied to compare pharmacokinetics and brain distribution of α-asaronol by different routes including intranasal administration, intragastric administration and intravenous injection. Results Maximum concentration in plasma (Cmax) of α-asaronol for intranasal administration was 11.39 ± 1.30 μg·mL-1 and the peak time (Tmax) was 2 min, which were comparable to those for intravenous injection, whiles Cmax was 6.71 ± 0.78 μg·mL-1 and Tmax was 10 min for intragastric administration. Compared with intravenous injection, the bioavailability of α-asaronol by intranasal and intragastric administration was 70.57% and 19.31%, respectively. α-asaronol was distributed in hippocampus, cerebellum, olfactory bulb and cerebral cortex after intranasal administration, especially that the brain targeting is highest in olfactory bulb. Conclusion Intranasal administration can import α-asaronol into the brain by nasal-brain pathway, which is an effective route to treat epilepsy with faster absorption, higher bioavailability and better brain targeting.
Key words:  α-asaronol  Epilepsy  Intranasal administration
Today's Visits:488    Total Visits:2383203
Website copyright:Editorial Board of Journal of Pharmaceutical Research     鲁ICP备17018036号-3     鲁公网安备 37010202001351号
Sponsored by:Shandong Institute for Food and Drug Control Shandong Pharmaceutical Association Address:No.2749 Xinluo Street,High-Tech Zone,Jinan,P.R.China Postcode:250101
Telephone Number:0531-81216586 Email :yaoxueyanjiu@163.com;yaoxueyanjiu@126.com
Technical Support:Beijing Qinyun Technology Co., Ltd.